SecProbe.io - Filing

CORRESP Filing

Nasus Pharma Ltd
Date: March 11, 2026 · CIK: 0002029039 · Accession: 0001493152-26-009621

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-293950

Date

March 11, 2026

Author

Chief

Form

CORRESP

Company

Nasus Pharma Ltd

Letter

Nasus Pharma Ltd.

P.O. Box 284

Tel Aviv, Israel 6100201

March 11, 2026

VIA EDGAR

Securities and Exchange Commission

Division of Corporation Finance

F Street, N.E.

Washington, DC 20549

RE: Nasus Pharma Ltd. (CIK 0002029039)

Registration Statement No. 333-293950 on Form F-1 (the "Registration Statement")

Ladies and Gentlemen:

Nasus Pharma Ltd. (the " Registrant ") hereby requests acceleration of the effectiveness of the above-referenced Registration Statement pursuant to Rule 461 under the Securities Act of 1933, as amended, so that it may become effective on March 13, 2026, at 4:30 p.m., Eastern Time, or as soon thereafter as is practicable.

The Registrant respectfully requests that it be notified of such effectiveness by an e-mail or phone call to Eric Victorson, Esq. of Sullivan & Worcester LLP at evictorson@sullivanlaw.com or (212) 660-3092.

Very
truly yours,
Nasus
Pharma Ltd.

Show Raw Text

CORRESP
 1
 filename1.htm

 Nasus
Pharma Ltd.

 P.O.
Box 284

 Tel
Aviv, Israel 6100201

 March
11, 2026

 VIA
EDGAR

 Securities
and Exchange Commission

 Division
of Corporation Finance

 100
F Street, N.E.

 Washington,
DC 20549

 RE:
 Nasus
 Pharma Ltd. (CIK 0002029039)

 Registration
 Statement No. 333-293950 on Form F-1 (the "Registration Statement")

 Ladies
and Gentlemen:

 Nasus
Pharma Ltd. (the " Registrant ") hereby requests acceleration of the effectiveness of the above-referenced Registration
Statement pursuant to Rule 461 under the Securities Act of 1933, as amended, so that it may become effective on March 13, 2026, at 4:30
p.m., Eastern Time, or as soon thereafter as is practicable.

 The
Registrant respectfully requests that it be notified of such effectiveness by an e-mail or phone call to Eric Victorson, Esq. of Sullivan
& Worcester LLP at evictorson@sullivanlaw.com or (212) 660-3092.

 Very
 truly yours,

 Nasus
 Pharma Ltd.

 By:
 /s/
 Dan Teleman

 Dan
 Teleman
 Chief
 Executive Officer